Gilead Sciences, Inc’s recent filing unveils that its 10% Owner GILEAD SCIENCES, INC. acquired Company’s shares for reported $15.0 million on Feb 18 ’25. In the deal valued at $11.00 per share,1,363,636 shares were bought. As a result of this transaction, GILEAD SCIENCES, INC. now holds 31,424,760 shares worth roughly $3.49 billion.
Then, Dickinson Andrew D sold 2,500 shares, generating $260,225 in total proceeds. Upon selling the shares at $104.09, the Chief Financial Officer now owns 169,061 shares.
Before that, ANDREW DICKINSON bought 2,500 shares. Gilead Sciences, Inc shares valued at $260,225 were divested by the Officer at a price of $104.09 per share.
Deutsche Bank upgraded its Gilead Sciences, Inc [GILD] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including DZ Bank’s analysts, who increased its forecast for the stock in mid February from “a Hold” to “a Buy”. Morgan Stanley also remained covering GILD and has increased its forecast on January 10, 2025 with a “an Overweight” recommendation from previously “an Equal-weight” rating.
Price Performance Review of GILD
On Friday, Gilead Sciences, Inc [NASDAQ:GILD] saw its stock jump 0.98% to $111.03. Over the last five days, the stock has gained 6.68%. Gilead Sciences, Inc shares have risen nearly 20.20% since the year began. Nevertheless, the stocks have risen 51.68% over the past one year. While a 52-week high of $111.03 was reached on 02/24/25, a 52-week low of $62.07 was recorded on 01/10/25. SMA at 50 days reached $95.59, while 200 days put it at $82.41.
Levels Of Support And Resistance For GILD Stock
The 24-hour chart illustrates a support level at 109.66, which if violated will result in even more drops to 108.28. On the upside, there is a resistance level at 112.20. A further resistance level may holdings at 113.36. The Relative Strength Index (RSI) on the 14-day chart is 77.06, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 7.44, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 5.51%. Stochastics %K at 95.82% indicates the stock is a selling.
The most recent change occurred on November 15, 2024 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $110 price target.
